Loading…
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-114M | $-127M | $-95M | -38.3% | - | - |
| 2024 | - | - | - | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2024 | 2025 |
|---|---|---|
| Total Revenue | - | 0 |
| Operating Revenue | - | 0 |
| Operating Expense | - | 113.54 |
| Research And Development | - | 93.12 |
| Selling General And Administration | - | 20.42 |
| Total Expenses | - | 113.54 |
| Operating Income | - | -113.54 |
| Total Operating Income As Reported | - | -113.54 |
| EBITDA | - | -113.52 |
| Normalized EBITDA | - | -113.52 |
| EBIT | - | -113.54 |
| Interest Income | - | 7.78 |
| Net Interest Income | - | 7.78 |
| Other Non Operating Income Expenses | - | -21.59 |
| Other Income Expense | - | -21.59 |
| Interest Income Non Operating | - | 7.78 |
| Net Non Operating Interest Income Expense | - | 7.78 |
| Pretax Income | - | -127.35 |
| Tax Provision | - | 0.06 |
| Tax Rate For Calcs | - | 0 |
| Tax Effect Of Unusual Items | - | 0 |
| Net Income Continuous Operations | - | -127.41 |
| Net Income From Continuing And Discontinued Operation | - | -127.41 |
| Net Income From Continuing Operation Net Minority Interest | - | -127.41 |
| Net Income | - | -127.41 |
| Net Income Common Stockholders | - | -127.41 |
| Net Income Including Noncontrolling Interests | - | -127.41 |
| Normalized Income | - | -127.41 |
| Diluted NI Availto Com Stockholders | - | -127.41 |
| Basic Average Shares | - | 31.36 |
| Diluted Average Shares | - | 31.36 |
| Reconciled Depreciation | - | 0.03 |
| General And Administrative Expense | - | 20.42 |
| Other Gand A | - | 7.73 |
| Salaries And Wages | - | 12.69 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Jade Biosciences, Inc.this co. | JBIO | $876M | - | -18.71 | -38.3% | - |
| Annexon, Inc. | ANNX | $893M | -4.32 | 4.22 | -97.7% | -3.54 |
| Pacira BioSciences, Inc. | PCRX | $892M | 126.89 | 1.29 | 1.0% | 8.75 |
| Xencor, Inc. | XNCR | $890M | - | 1.40 | -14.5% | - |
| Cullinan Therapeutics, Inc. | CGEM | $887M | -4.03 |
| 2.17 |
| -53.8% |
| -3.32 |
| MeiraGTx Holdings plc | MGTX | $886M | -7.76 | -152.99 | 1971.4% | -10.17 |
| Certara, Inc. | CERT | $873M | -547.16 | 0.82 | -0.2% | 9.65 |
| Talkspace, Inc. | TALK | $871M | 111.78 | 7.44 | 6.7% | 129.10 |
| Arbutus Biopharma Corporation | ABUS | $859M | -25.65 | 11.22 | -43.7% | -25.48 |
| Peer Median | - | -4.32 | 1.79 | -7.3% | -3.32 | |